Nathalie Adda Net Worth

The estimated Net Worth of Nathalie Adda is at least $5.12 Million dollars as of 1 April 2022. Nathalie Adda owns over 83,344 units of Enanta Pharmaceuticals Inc stock worth over $815,915 and over the last 9 years he sold ENTA stock worth over $2,685,553. In addition, he makes $1,614,800 as Senior Vice President and Chief Medical Officer at Enanta Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Nathalie Adda ENTA stock SEC Form 4 insiders trading

Nathalie has made over 14 trades of the Enanta Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 83,344 units of ENTA stock worth $3,386,267 on 1 April 2022.

The largest trade he's ever made was exercising 83,344 units of Enanta Pharmaceuticals Inc stock on 1 April 2022 worth over $3,386,267. On average, Nathalie trades about 7,488 units every 52 days since 2015. As of 1 April 2022 he still owns at least 67,767 units of Enanta Pharmaceuticals Inc stock.

You can see the complete history of Nathalie Adda stock trades at the bottom of the page.

Nathalie Adda biography

Dr. Nathalie Adda M.D. is Senior Vice President and Chief Medical Officer of the Company, since June 2015. Prior to joining Enanta, Dr. Adda was Chief Medical Officer, VP Clinical Development, Medical and Regulatory Affairs at Transgene SA, where she led the Oncology and Infectious Disease programs since 2012. From 2006 to 2012, she was Senior Medical Director and the medical lead for the Incivek® (telaprevir) Clinical Program at Vertex Pharmaceuticals, Inc. Earlier in her career, Dr. Adda held medical and research positions at Gilead, Triangle Pharmaceuticals and Boehringer Ingelheim, where she worked on programs for infectious diseases such as human immunodeficiency virus, hepatitis B virus and hepatitis C virus. Dr. Adda is a graduate of the University of Paris, where she received a Doctorate in Medicine, as well as a Master’s Degree in Biostatistics, and where she did post- graduate work in infectious diseases.

What is the salary of Nathalie Adda?

As the Senior Vice President and Chief Medical Officer of Enanta Pharmaceuticals Inc, the total compensation of Nathalie Adda at Enanta Pharmaceuticals Inc is $1,614,800. There are 2 executives at Enanta Pharmaceuticals Inc getting paid more, with Jay Luly having the highest compensation of $4,483,500.

How old is Nathalie Adda?

Nathalie Adda is 54, he's been the Senior Vice President and Chief Medical Officer of Enanta Pharmaceuticals Inc since 2015. There are 14 older and 1 younger executives at Enanta Pharmaceuticals Inc. The oldest executive at Enanta Pharmaceuticals Inc is Bruce Carter, 76, who is the Independent Non-Executive Chairman of the Board.

What's Nathalie Adda's mailing address?

Nathalie's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.

Insiders trading at Enanta Pharmaceuticals Inc

Over the last 11 years, insiders at Enanta Pharmaceuticals Inc have traded over $72,640,961 worth of Enanta Pharmaceuticals Inc stock and bought 354,891 units worth $5,071,651 . The most active insiders traders include Jay R. Luly, V Life Science Ventures Gmb..., and Yat Sun Or. On average, Enanta Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $285,155. The most recent stock trade was executed by Scott T. Rottinghaus on 11 July 2024, trading 11,945 units of ENTA stock currently worth $190,762.

What does Enanta Pharmaceuticals Inc do?

enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.

Complete history of Nathalie Adda stock trades at Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc executives and stock owners

Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jay Luly,
  President, Chief Executive Officer, Director
• Yat Sun Or,
  Senior Vice President - Research & Development, Chief Scientific Officer
• Nathalie Adda,
  Senior Vice President and Chief Medical Officer
• Paul Mellett,
  Chief Financial Officer, Senior Vice President - Finance & Administration
• Nathaniel Gardiner,
  Senior Vice President, General Counsel
• Dr. Jay R. Luly,
  Pres, CEO & Director
• Dr. Yat Sun Or,
  Sr. VP of R&D and Chief Scientific Officer
• Dr. Nathalie Adda,
  Sr. VP & Chief Medical Officer
• Nathaniel S. Gardiner J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Paul J. Mellett Jr.,
  Sr. VP of Fin. & Admin. and CFO
• Bruce Carter,
  Independent Non-Executive Chairman of the Board
• Terry Vance,
  Independent Director
• George Golumbeski,
  Independent Director
• Lesley Russell,
  Independent Director
• Kristine Peterson,
  Independent Director
• Mark Foletta,
  Independent Director
• Carol Miceli,
  Director, Investor Relations
• Brendan Luu,
  Sr. VP of Bus. Devel.
• Tara Lynn Kieffer Ph.D.,
  Sr. VP of New Product Strategy & Devel.
• Jennifer Viera,
  Sr. Director of Investor Relations & Corp. Communications
• Ernst Guenter Afting,
  Director
• Tim Ocain,
  Senior Vice President
• Stephen Jr. Buckley,
  Director
• V Life Science Ventures Gmb...,
  
• V Life Science Ventures Gmb...,
  
• Helmut Schuhsler,
  Director
• David Poorvin,
  Director
• Capital Granite, L.P.M Rna ...,
  
• Marc E. Goldberg,
  Director
• Gregory L. Verdine,
  Director
• & Co Ltd Shionogi,
  10% owner
• Yujiro S Hata,
  Director
• Brendan Luu,
  Chief Business Officer
• Scott T. Rottinghaus,
  Chief Medical Officer
• Tara Lynn Kieffer,
  Chief Product Strategy Officer
• Matthew Paul Kowalsky,
  Chief Legal Officer